Skip to main content
NCBI home page
Environmental Health Perspectives logoLink to Environmental Health Perspectives
. 1994 Nov;102(Suppl 9):35–38. doi: 10.1289/ehp.94102s935

Interactions between clinically used drugs and oral contraceptives.

H M Bolt 1
PMCID: PMC1566787  PMID: 7698081

Abstract

Metabolism of contraceptive compounds may be influenced by various drugs. Of clinical importance is induction by barbiturates, by diphenylhydantoin, and especially by rifampicin, of enzymes that are responsible for degradation of estrogens. The major target is the hepatic microsomal estrogen-2-hydroxylase (cytochrome P450 3A4). Another type of interaction of drugs with disposition and effectiveness of estrogens is impairment of their enterohepatic circulation. This may be due to absorption of biliary estrogen conjugates (e.g., by cholestyramine) or to insufficient cleavage of the conjugate by intestinal bacteria, the latter being observed after administration of antibiotics (e.g., ampicillin, neomycin).

Full text

PDF
35

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adlercreutz H., Martin F., Tikkanen M. J., Pulkkinen M. Effect of ampicillin administration on the excretion of twelve oestrogens in pregnancy urine. Acta Endocrinol (Copenh) 1975 Nov;80(3):551–557. doi: 10.1530/acta.0.0800551. [DOI] [PubMed] [Google Scholar]
  2. Altschuler S. L., Valenteen J. W. Amenorrhea following rifampin administration during oral contraceptive use. Obstet Gynecol. 1974 Nov;44(5):771–772. [PubMed] [Google Scholar]
  3. Bolt H. M., Bolt M., Kappus H. Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man. Acta Endocrinol (Copenh) 1977 May;85(1):189–197. doi: 10.1530/acta.0.0850189. [DOI] [PubMed] [Google Scholar]
  4. Bolt H. M., Bolt W. H. Pharmacokinetics of mestranol in man in relation to its oestrogenic activity. Eur J Clin Pharmacol. 1974 Jul 26;7(4):295–305. doi: 10.1007/BF00560348. [DOI] [PubMed] [Google Scholar]
  5. Bolt H. M. Effects on endocrine systems by influencing hepatic metabolism of steroid hormones. Pharmacol Ther B. 1979;5(1-3):365–368. doi: 10.1016/0163-7258(79)90106-2. [DOI] [PubMed] [Google Scholar]
  6. Bolt H. M., Kappus H., Bolt M. Effect of rifampicin treatment on the metabolism of oestradiol and 17alpha-ethinyloestradiol by human liver microsomes. Eur J Clin Pharmacol. 1975 Jun 13;8(5):301–307. doi: 10.1007/BF00562654. [DOI] [PubMed] [Google Scholar]
  7. Bolt H. M., Kappus H., Remmer H. Studies on the metabolism of ethynylestradiol in vitro and in vivo: the significance of 2-hydroxylation and the formation of polar products. Xenobiotica. 1973 Dec;3(12):773–785. doi: 10.3109/00498257309151602. [DOI] [PubMed] [Google Scholar]
  8. Bolt H. M., Kassel H. Effects of insecticide synergists on microsomal oxidation of estradiol and ethynylestradiol and on microsomal drug metabolism. Xenobiotica. 1976 Jan;6(1):33–38. doi: 10.3109/00498257609151609. [DOI] [PubMed] [Google Scholar]
  9. Bolt H. M. Metabolism of estrogens--natural and synthetic. Pharmacol Ther. 1979;4(1):155–181. doi: 10.1016/0163-7258(79)90018-4. [DOI] [PubMed] [Google Scholar]
  10. Bolt W., Ritzl F., Bolt H. M. Enterohepatischer Kreislauf und Sexualhormon-Stoffwechsel beim Menschen. Munch Med Wochenschr. 1966 Apr 22;108(16):875–878. [PubMed] [Google Scholar]
  11. Braselton W. E., Lin T. J., Mills T. M., Ellegood J. O., Mahesh V. B. Identification and measurement by gas chromatography-mass spectrometry of norethindrone and metabolites in human urine and blood. J Steroid Biochem. 1977 Jan;8(1):9–18. doi: 10.1016/0022-4731(77)90210-2. [DOI] [PubMed] [Google Scholar]
  12. Brewster D., Jones R. S., Symons A. M. Effects of neomycin on the biliary excretion and enterohepatic circulation of mestranol and 17beta-oestradiol. Biochem Pharmacol. 1977 May 15;26(10):943–946. doi: 10.1016/0006-2952(77)90471-3. [DOI] [PubMed] [Google Scholar]
  13. Buffington G. A., Dominguez J. H., Piering W. F., Hebert L. A., Kauffman H. M., Jr, Lemann J., Jr Interaction of rifampin and glucocorticoids. Adverse effect on renal allograft function. JAMA. 1976 Oct 25;236(17):1958–1960. [PubMed] [Google Scholar]
  14. Guengerich F. P. Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene. Chem Res Toxicol. 1990 Jul-Aug;3(4):363–371. doi: 10.1021/tx00016a015. [DOI] [PubMed] [Google Scholar]
  15. Handy R. W., Palmer K. H., Wall M. E., Piantadosi C. The metabolism of antifertility steroids. The in virto metabolism of chlormadinone acetate. Drug Metab Dispos. 1974 May-Jun;2(3):214–220. [PubMed] [Google Scholar]
  16. Helton E. D., Goldzieher J. W. Metabolism of ethynyl estrogens. J Toxicol Environ Health. 1977 Sep;3(1-2):231–241. doi: 10.1080/15287397709529562. [DOI] [PubMed] [Google Scholar]
  17. Janz D., Schmidt D. Letter: Anti-epileptic drugs and failure of oral contraceptives. Lancet. 1974 Jun 1;1(7866):1113–1113. doi: 10.1016/s0140-6736(74)90593-5. [DOI] [PubMed] [Google Scholar]
  18. Kropp R. Rifampicin und Ovulationshemmer. Prax Pneumol. 1974 May;28(5):270–272. [PubMed] [Google Scholar]
  19. Levin W., Welch R. M., Conney A. H. Decreased uterotropic potency of oral contraceptives in rats pretreated with phenobarbital. Endocrinology. 1968 Jul;83(1):149–156. doi: 10.1210/endo-83-1-149. [DOI] [PubMed] [Google Scholar]
  20. Lopez del Pino V., Bolt H. M. Die Thioacetamid-vergiftete Ratte als tierexperimentelles Modell für endokrinologische Untersuchungen des Ostrogen-Stoffwechsels unter chronischer Leberschädigung. Endokrinologie. 1975 Dec;66(3):250–254. [PubMed] [Google Scholar]
  21. López del Pino V., Bolt H. M. Effects of hepatotoxic agents on hepatic microsomal metabolism of estrogens in the rat. Arzneimittelforschung. 1977;27(11):2117–2120. [PubMed] [Google Scholar]
  22. Michot F., Bürgi M., Büttner J. Rimactan (Rifampizin) und Antikoagulantientherapie. Schweiz Med Wochenschr. 1970 Mar 28;100(13):583–584. [PubMed] [Google Scholar]
  23. Nocke-Finck L., Breuer H., Reimers D. Wirkung von Rifampicin auf den Menstruationszyklus und die Ostrogenausscheidung bei Einnahme oraler Kontrazeptiva. Dtsch Med Wochenschr. 1973 Aug 11;98(33):1521–1523. doi: 10.1055/s-0028-1107071. [DOI] [PubMed] [Google Scholar]
  25. Pessayre D., Mazel P. Induction and inhibition of hepatic drug metabolizing enzymes by rifampin. Biochem Pharmacol. 1976 Apr 15;25(8):943–949. doi: 10.1016/0006-2952(76)90320-8. [DOI] [PubMed] [Google Scholar]
  26. Peters U., Hausamen T. U., Grosse-Brockhoff F. Einfluss von Tuberkulostatika auf die Pharmakokinetik des Digitoxins. Dtsch Med Wochenschr. 1974 Nov 22;99(47):2381–2386. doi: 10.1055/s-0028-1108142. [DOI] [PubMed] [Google Scholar]
  27. Reimers D., Jezek A. Rifampicin und andere Antituberkulotika bei gleichzeitiger oraler Kontrazeption. Prax Pneumol. 1971 May;25(5):255–262. [PubMed] [Google Scholar]
  28. Remmer H., Schoene B., Fleischmann R. A. Induction of the unspecific microsomal hydroxylase in the human liver. Drug Metab Dispos. 1973 Jan-Feb;1(1):224–230. [PubMed] [Google Scholar]
  29. SANDBERG A. A., SLAUNWHITE W. R., Jr Studies on phenolic steroids in human subjects. II. The metabolic fate and hepato-biliary-enteric circulation of C14-estrone and C14-estradiol in women. J Clin Invest. 1957 Aug;36(8):1266–1278. doi: 10.1172/JCI103524. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Self T. H., Mann R. B. Interaction of rifampin and warfarin. Chest. 1975 Apr;67(4):490–491. doi: 10.1378/chest.67.4.490. [DOI] [PubMed] [Google Scholar]
  31. Skolnick J. L., Stoler B. S., Katz D. B., Anderson W. H. Rifampin, oral contraceptives, and pregnancy. JAMA. 1976 Sep 20;236(12):1382–1382. [PubMed] [Google Scholar]
  32. Syvälahti E. K., Pihlajamäki K. K., Iisalo E. J. Letter: Rifampicin and drug metabolism. Lancet. 1974 Jul 27;2(7874):232–233. doi: 10.1016/s0140-6736(74)91547-5. [DOI] [PubMed] [Google Scholar]
  33. Wenzel M., Stahl H. J. Verstärkte Hydroxylierung von Ostrogenen beim Menschen nach Arzneimittelgabe Nachweis durch HTO-Analyse des Körperwassers. Hoppe Seylers Z Physiol Chem. 1970 Jun;351(6):761–762. [PubMed] [Google Scholar]
  34. Williams M. C., Helton E. D., Goldzieher J. W. The urinary metabolites of 17alpha-ethynylestradiol-9alpha,11xi-3H in women. Chromatographic profiling and indentification of ethynyl and non-ethynyl compounds. Steroids. 1975 Feb;25(2):229–246. doi: 10.1016/s0039-128x(75)90135-x. [DOI] [PubMed] [Google Scholar]
  35. Yamada S., Iwai K. Letter: Induction of hepatic cortisol-6-hydroxylase by rifampicin. Lancet. 1976 Aug 14;2(7981):366–367. doi: 10.1016/s0140-6736(76)92621-0. [DOI] [PubMed] [Google Scholar]
  36. Zilly W., Breimer D. D., Richter E. Induction of drug metabolism in man after rifampicin treatment measured by increased hexobarbital and tolbutamide clearance. Eur J Clin Pharmacol. 1975 Dec 19;9(2-3):219–227. doi: 10.1007/BF00614021. [DOI] [PubMed] [Google Scholar]
  37. Zilly W., Breimer D. D., Richter E. Stimulation of drug metabolism by rifampicin in patients with cirrhosis or cholestasis measured by increased hexobarbital and tolbutamide clearance. Eur J Clin Pharmacol. 1977 Apr 20;11(4):287–293. doi: 10.1007/BF00607679. [DOI] [PubMed] [Google Scholar]
  38. Zumoff B., Fishman J., Gallagher T. F., Hellman L. Estradiol metabolism in cirrhosis. J Clin Invest. 1968 Jan;47(1):20–25. doi: 10.1172/JCI105709. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. del Pino V. L., Bolt H. M. Der zeitliche Verlauf der durch Thioacetamid indurzieten Veränderungen des Ostrogenstoffwechsels in der Rattenleber. Endokrinologie. 1976;68(2):137–142. [PubMed] [Google Scholar]

Articles from Environmental Health Perspectives are provided here courtesy of National Institute of Environmental Health Sciences

RESOURCES